Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C14H18Cl2N2O6S |
| Molecular Weight | 413.274 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CS(=O)(=O)C1=CC=C(C=C1)[C@@H](O)[C@@H](COC(=O)CN)NC(=O)C(Cl)Cl
InChI
InChIKey=AMGKHLVPQHMHGQ-ZYHUDNBSSA-N
InChI=1S/C14H18Cl2N2O6S/c1-25(22,23)9-4-2-8(3-5-9)12(20)10(7-24-11(19)6-17)18-14(21)13(15)16/h2-5,10,12-13,20H,6-7,17H2,1H3,(H,18,21)/t10-,12-/m1/s1
| Molecular Formula | C14H18Cl2N2O6S |
| Molecular Weight | 413.274 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.mims.com/thailand/drug/info/urfamycinCurator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15224555 and https://www.drugs.com/international/urfamycin.html
Sources: http://www.mims.com/thailand/drug/info/urfamycin
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/15224555 and https://www.drugs.com/international/urfamycin.html
Thiamphenicol aminoacetate is an antibiotic. It is the methyl-sulfonyl analogue of chloramphenicol and has a similar spectrum of activity, but is 2.5 to 5 times as potent. It is used in many countries as a veterinary antibiotic, but is available in China, Morocco and Italy for use in humans. Thiamphenicol aminoacetate is reported as an ingredient of Urfamycin in Ecuador, Indonesia, Italy, Taiwan, Thailand, Turkey, Japan. It is indicated for the treatment of GUT, hepatobiliary, respiratory tract, enteric tract infections, typhoid, paratyphoid fever and salmonellosis, brucellosis.
Approval Year
Targets
| Primary Target | Pharmacology | Condition | Potency |
|---|---|---|---|
Target ID: Neisseria gonorrhoeae growth Sources: https://www.ncbi.nlm.nih.gov/pubmed/2113717 |
|||
Target ID: Moraxella catarrhalis growth Sources: https://www.ncbi.nlm.nih.gov/pubmed/11367873 |
|||
Target ID: Streptococcus pneumoniae growth Sources: https://www.ncbi.nlm.nih.gov/pubmed/11367873 |
|||
Target ID: Haemophilus influenzae growth Sources: https://www.ncbi.nlm.nih.gov/pubmed/11367873 |
Conditions
| Condition | Modality | Targets | Highest Phase | Product |
|---|---|---|---|---|
| Curative | Urfamycin Approved UseGUT, hepatobiliary, resp tract, enteric tract infections, typhoid, paratyphoid fever & salmonellosis, brucellosis. |
|||
| Curative | Urfamycin Approved UseGUT, hepatobiliary, resp tract, enteric tract infections, typhoid, paratyphoid fever & salmonellosis, brucellosis. |
|||
| Curative | Urfamycin Approved UseGUT, hepatobiliary, resp tract, enteric tract infections, typhoid, paratyphoid fever & salmonellosis, brucellosis. |
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
26.6 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
THIAMPHENICOL AMINOACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
38.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
THIAMPHENICOL AMINOACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
66.1 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
1500 mg single, intravenous dose: 1500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
THIAMPHENICOL AMINOACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
30.4 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
THIAMPHENICOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
53.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
THIAMPHENICOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
78.5 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
1500 mg single, intravenous dose: 1500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
THIAMPHENICOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
18.58 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
THIAMPHENICOL AMINOACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
29.56 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
THIAMPHENICOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
849.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
THIAMPHENICOL AMINOACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
1305.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
THIAMPHENICOL AMINOACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
2315.9 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
1500 mg single, intravenous dose: 1500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
THIAMPHENICOL AMINOACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
4509 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
THIAMPHENICOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
7506.5 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
THIAMPHENICOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
12613.3 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
1500 mg single, intravenous dose: 1500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
THIAMPHENICOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
234.1 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
THIAMPHENICOL AMINOACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
|
4114.2 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
THIAMPHENICOL plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
17.6 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
500 mg single, intravenous dose: 500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
THIAMPHENICOL AMINOACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
16.8 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
1000 mg single, intravenous dose: 1000 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
THIAMPHENICOL AMINOACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
16.8 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
1500 mg single, intravenous dose: 1500 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
THIAMPHENICOL AMINOACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
|
20.7 min EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/24597465/ |
500 mg 2 times / day multiple, intravenous dose: 500 mg route of administration: Intravenous experiment type: MULTIPLE co-administered: |
THIAMPHENICOL AMINOACETATE plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
80% EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/7394975/ |
THIAMPHENICOL unknown | Homo sapiens |
Doses
| Dose | Population | Adverse events |
|---|---|---|
2 g single, intraperineal Highest studied dose Dose: 2 g Route: intraperineal Route: single Dose: 2 g Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M Food Status: UNKNOWN Sources: |
|
631 mg 2 times / day multiple, respiratory Studied dose Dose: 631 mg, 2 times / day Route: respiratory Route: multiple Dose: 631 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
Disc. AE: Asthma, Nausea... AEs leading to discontinuation/dose reduction: Asthma (1.1%) Sources: Nausea (3.4%) Vomiting (3.4%) |
AEs
| AE | Significance | Dose | Population |
|---|---|---|---|
| Asthma | 1.1% Disc. AE |
631 mg 2 times / day multiple, respiratory Studied dose Dose: 631 mg, 2 times / day Route: respiratory Route: multiple Dose: 631 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Nausea | 3.4% Disc. AE |
631 mg 2 times / day multiple, respiratory Studied dose Dose: 631 mg, 2 times / day Route: respiratory Route: multiple Dose: 631 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
| Vomiting | 3.4% Disc. AE |
631 mg 2 times / day multiple, respiratory Studied dose Dose: 631 mg, 2 times / day Route: respiratory Route: multiple Dose: 631 mg, 2 times / day Sources: |
unhealthy, ADULT Health Status: unhealthy Age Group: ADULT Sex: M+F Food Status: UNKNOWN Sources: |
PubMed
| Title | Date | PubMed |
|---|---|---|
| Comparative in vitro activity of thiamphenicol-glycinate and thiamphenicol-glycinate-acetylcysteinate and other antimicrobials against respiratory pathogens. | 2001 |
|
| [Re-evaluation of single-dose treatment with thiamphenicol and spectinomycin of uncomplicated male gonococcal urethritis]. | 1987 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: http://www.mims.com/thailand/drug/info/urfamycin
Adult 500 mg 8 hrly. Childn 20-30 mg/kg/day. Gonorrhea 2.5 g/day for 1-2 days.
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/11367873
THIAMPHENICOL AMINOACETATE inhibited M. catarrhalis with MIC90 0.5 ug/ml
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 19:32:33 GMT 2025
by
admin
on
Mon Mar 31 19:32:33 GMT 2025
|
| Record UNII |
W5H94CY6V6
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
DTXSID7048326
Created by
admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
|
PRIMARY | |||
|
C028813
Created by
admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
|
PRIMARY | |||
|
115817
Created by
admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
|
PRIMARY | |||
|
W5H94CY6V6
Created by
admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
|
PRIMARY | |||
|
2393-92-2
Created by
admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
|
PRIMARY | |||
|
100000084804
Created by
admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
|
PRIMARY | |||
|
163416
Created by
admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
|
PRIMARY | RxNorm | ||
|
2625
Created by
admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
|
PRIMARY | |||
|
SUB04801MIG
Created by
admin on Mon Mar 31 19:32:33 GMT 2025 , Edited by admin on Mon Mar 31 19:32:33 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
SALT/SOLVATE -> PARENT |
|
||
|
|
SALT/SOLVATE -> PARENT |